BioSpace News Archive

Medical device and technology company Lazurite™ Holdings LLC announced that it has been selected to participate in the MedTech Innovator 2022 Road Tour Mid-Stage pitch event in Boston, May 10-11.

Vivalink, a leading provider of digital healthcare solutions, announces availability of the world’s first multi-vital blood pressure patch for remote patient monitoring for use in commercial research and development.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that its license and development partner, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun”), presented at this year’s Chinese Society of Clinical Oncology (CSCO) Guideline Conference (April 23-24, 2022) Phase 1 data for its anti-HER2-ADC, A166.

ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its selective organ targeting (SORT) lipid nanoparticles (LNP) delivery platform, today announced that it will present preclinical data from its mRNA-based therapeutic programs in cystic fibrosis and primary ciliary dyskinesia at the American Thoracic Society’s ATS 2022 International Conference.

n-Lorem announced today the formation of Silence ALS, an initiative that aligns Columbia University and n-Lorem in support of the characterization of nano-rare amyotrophic lateral sclerosis (ALS) patients.

Cosmos Holdings, Inc. announced it has appointed finance veteran Dr. Anastasios Aslidis to the Board of Directors and as a member of the Board’s audit committee.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), today announces it has entered into definitive agreements to acquire a majority stake in NanoSynex Ltd., an Israeli-based developer of next generation diagnostics technology.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its Phase 2, randomized, double-blinded, placebo-controlled trial of dazodalibep (HZN-4920) in rheumatoid arthritis (RA) met the primary endpoint.

Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today the company has advanced into its Good Laboratory Practice (GLP) toxicology study.

Matica Biotechnology, Inc. announced the opening of its new 45,000-square-foot facility dedicated to the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other genetic medicines.